Novogene offers CLIA-validated Whole Exome Sequencing (WES) for investigation or diagnoses of genetic variations underlying cancers, Mendelian diseases, and complex human disorders.
Whole Exome Sequencing is gaining popularity as a viable and cost-effective alternative to Whole Genome Sequencing: WES targets all protein-coding regions (~1% of the whole genome) responsible for 85% of all disease-causing mutations.
Clinical WES Workflow
Download Brochure to Learn More
Contact Us / Request Quote
8801 Folsom Blvd #290, Sacramento, CA 95826
Copyright©2011-2020 Novogene Corporation
All Rights Reserved. Information and specifications are subject to change at any time without notice.
The field is required.